Market Cap | 154.98M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -26.34M | Forward P/E | -0.02 | EPS next Y | - | 50D Avg Chg | - |
Sales | 10M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 25.00% |
Dividend | N/A | Price/Book | 2.50 | EPS next 5Y | - | 52W High Chg | -18.00% |
Recommedations | 1.50 | Quick Ratio | 4.57 | Shares Outstanding | 140.27M | 52W Low Chg | 151.00% |
Insider Own | 0.54% | ROA | -20.59% | Shares Float | 440.01M | Beta | - |
Inst Own | 60.03% | ROE | -46.10% | Shares Shorted/Prior | 2.83M/2.33M | Price | 1.24 |
Gross Margin | 70.79% | Profit Margin | -263.41% | Avg. Volume | 1,930,119 | Target Price | 6.25 |
Oper. Margin | -256.48% | Earnings Date | Mar 29 | Volume | 485,900 | Change | -8.15% |
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
Cantor Fitzgerald | Overweight | May 16, 24 |
Needham | Buy | May 16, 24 |
Needham | Buy | Apr 10, 24 |
Cantor Fitzgerald | Overweight | Mar 28, 24 |
Needham | Buy | Mar 28, 24 |
Cantor Fitzgerald | Overweight | Mar 22, 24 |
Cantor Fitzgerald | Overweight | Sep 8, 23 |
Needham | Buy | Sep 8, 23 |
Needham | Buy | Aug 23, 23 |